Arcus Advances Quemliclustat With Completed Phase 1 Metabolism Study

Arcus Biosciences (RCUS) announced an update on their ongoing clinical study.

Arcus Biosciences, Inc. is running a Phase 1 study called “A Phase 1, Open-Label Study to Characterize the Metabolism, Excretion, and Mass Balance of a Single Intravenous Dose of 100 mg Containing 75 µCi of [14C]-Quemliclustat in Healthy Adult Male Participants.” The aim is to understand how the body handles quemliclustat, a key early step before wider testing and any future commercial use.

The study tests a single intravenous dose of [14C]-labeled quemliclustat in healthy men. The goal is to track how the drug moves through the body and how it exits, by measuring total radioactivity in blood, urine, and feces.

This is an interventional Phase 1 trial with one treatment group and no control arm. It is open-label, meaning both researchers and participants know what is given, and the main purpose is basic science rather than direct treatment of disease.

The trial started after its first submission on January 16, 2026, marking the formal launch of the study plan. The last update was filed on April 29, 2026, signaling that Arcus has refreshed public information and that the record reflects completed status and the latest data flow.

For investors, this update confirms that Arcus is advancing quemliclustat through standard early safety and metabolism work, which helps de-risk later clinical stages. While Phase 1 data in healthy volunteers rarely move RCUS stock sharply on their own, they support the company’s broader pipeline story and position it against other oncology-focused small caps pursuing novel metabolism targets.

The quemliclustat metabolism study is completed and recently updated, with full details available on the ClinicalTrials.gov portal.

To learn more about RCUS’s potential, visit the Arcus Biosciences drug pipeline page.